Brun-Vézinet F - Search Results

1

Comparative assessment of quantitative HIV viraemia assays.

Rouzioux C, Puel J, Agut H, Brun-Vézinet F, Ferchal F, Tamalet C, Descamps P, Fleury H. Rouzioux C, et al. AIDS. 1992 Apr;6(4):373-7. doi: 10.1097/00002030-199204000-00003. AIDS. 1992. PMID: 1352105

2

Short-term evaluation of zidovudine-treated patients: decrease in plasma and cellular viraemia titres.

Tamalet C, Masquelier B, Ferchal F, Agut H, Puel J, Brun-Vézinet F, Fleury H, Rouzioux C. Tamalet C, et al. AIDS. 1992 Nov;6(11):1403-4. AIDS. 1992. PMID: 1361750 No abstract available.

3

HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase.

Brun-Vézinet F, Ingrand D, Deforges L, Gochi K, Ferchal F, Schmitt MP, Jung M, Masquelier B, Aubert J, Buffet-Janvresse C, et al. Brun-Vézinet F, et al. J Virol Methods. 1992 May;37(2):177-88. doi: 10.1016/0166-0934(92)90045-f. J Virol Methods. 1992. PMID: 1375948

4

LAV/HTLV-III antibodies in connective tissue diseases.

Gioud-Paquet M, Kahn MF, Rouzioux C, Brun-Vezinet F, Rey MA. Gioud-Paquet M, et al. Lancet. 1985 Sep 7;2(8454):554. doi: 10.1016/s0140-6736(85)90489-1. Lancet. 1985. PMID: 2863569 No abstract available.

5

Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.

Le Moing V, Chêne G, Carrieri MP, Alioum A, Brun-Vézinet F, Piroth L, Cassuto JP, Moatti JP, Raffi F, Leport C; Aproco Study Group. Le Moing V, et al. AIDS. 2002 Jan 4;16(1):21-9. doi: 10.1097/00002030-200201040-00004. AIDS. 2002. PMID: 11741159 Clinical Trial.

6

Final analysis of the Trilège induction-maintenance trial: results at 18 months.

Flandre P, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, Harel M, Hazebrouck S, Pialoux G, Aboulker JP, Brun Vezinet F. Flandre P, et al. AIDS. 2002 Mar 8;16(4):561-8. doi: 10.1097/00002030-200203080-00007. AIDS. 2002. PMID: 11872999 Clinical Trial.

7

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group. Meynard JL, et al. AIDS. 2002 Mar 29;16(5):727-36. doi: 10.1097/00002030-200203290-00008. AIDS. 2002. PMID: 11964529 Clinical Trial.

8

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.

Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group. Descamps D, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. doi: 10.1097/00126334-200212150-00002. J Acquir Immune Defic Syndr. 2002. PMID: 12473833 Clinical Trial.

9

Clinically relevant interpretation of genotype for resistance to abacavir.

Brun-Vézinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M, Costagliola D; Narval (ANRS 088) Study group. Brun-Vézinet F, et al. AIDS. 2003 Aug 15;17(12):1795-802. doi: 10.1097/00002030-200308150-00008. AIDS. 2003. PMID: 12891065

10

Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.

Matheron S, Pueyo S, Damond F, Simon F, Leprêtre A, Campa P, Salamon R, Chêne G, Brun-Vezinet F; French HIV-2 Cohort Study Group. Matheron S, et al. AIDS. 2003 Dec 5;17(18):2593-601. doi: 10.1097/00002030-200312050-00006. AIDS. 2003. PMID: 14685053

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

358 results

Search Page

Filters